Pfizer to acquire cancer therapeutics firm Trillium in $2.3bn deal
The acquisition is expected to benefit Pfizer with Trillium’s next-generation, investigational immuno-therapeutics for haematological malignancies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Aug 21
The acquisition is expected to benefit Pfizer with Trillium’s next-generation, investigational immuno-therapeutics for haematological malignancies
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Aug 21
The expansion is said to increase the company’s capability to manufacture complex APIs and generate new jobs at…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Aug 21
With the acquisition, Bayer will obtain full rights to Vividion’s discovery platform that includes chemoproteomic screening technology, an…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Aug 21
SoftBank’s investment was driven by Roche’s subsidiary Genentech, which focuses on drug discovery and development, and is believed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Jul 21
The acquisition includes a portfolio of early-stage oncology assets, including a Phase 1 bispecific antibody for advanced prostate…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Jul 21
The jury found that the Novartis failed to prove that patents were invalid and concluded that the infringement…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Jul 21
With the acquisition, AstraZeneca now has an enhanced presence in rare diseases and immunology fields, using Alexion’s complement-biology…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Jul 21
The sale is part of Sanofi’s strategy to simplify its consumer healthcare portfolio and advance its growth
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jun 21
The US government is committed to buy around 1.7 million courses of molnupiravir upon FDA Emergency Use Authorisation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 May 21
AstraZeneca recently received the US Federal Trade Commission (FTC) approval for the proposed acquisition of Alexion
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates